LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

31.02 -0.93

Buy Sell

Overview

Share price change

24h

Current

Min

31.02

Max

32.1

Key metrics
By Trading Economics
Income	-28M 22M
Sales	4.3M 244M
P/E Sector Avg	11.723 49.8
Profit margin	9.224
Employees	293
EBITDA	-22M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+38.26% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	338M 1.9B
Previous open	31.95
Previous close	31.02

News Sentiment

By Acuity

58%

42%

293 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 maj 2026, 23:58 UTC

Earnings

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 maj 2026, 22:57 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 maj 2026, 23:52 UTC

Earnings

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 maj 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 maj 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 maj 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 maj 2026, 23:11 UTC

Earnings

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 maj 2026, 23:06 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 maj 2026, 23:05 UTC

Earnings

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 maj 2026, 23:04 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 maj 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 maj 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 maj 2026, 23:02 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 maj 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 maj 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 maj 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 maj 2026, 22:42 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 maj 2026, 22:33 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 maj 2026, 22:32 UTC

Earnings

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 maj 2026, 22:31 UTC

Earnings

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 maj 2026, 22:31 UTC

Earnings

Macquarie: 68% of FY Income From International >MQG.AU

7 maj 2026, 22:30 UTC

Earnings

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 maj 2026, 22:30 UTC

Earnings

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 maj 2026, 22:29 UTC

Earnings

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 maj 2026, 22:28 UTC

Earnings

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 maj 2026, 22:28 UTC

Earnings

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 maj 2026, 22:27 UTC

Earnings

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 maj 2026, 22:27 UTC

Earnings

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 maj 2026, 22:26 UTC

Earnings

Macquarie to End Share Buyback Extended in November>MQG.AU

7 maj 2026, 22:25 UTC

Earnings

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

38.26% upside

12 Months Forecast

Average 43.44 USD 38.26%

High 72 USD

Low 28 USD

Based on 9 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

293 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.